A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read an analysis of MRNA stock now.

Merck said it expects the actions under the restructuring program to result in annual cost savings of approximately $1.7 billion, which will be substantially realized by the end of 2027.

The American Academy of Pediatrics is splitting from the federal government in its recommendations on which children should ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

The health and human services secretary, Robert F. Kennedy Jr., is accusing the American Academy of Pediatrics of a ...

As biotech is making a push to protect cattle from the screwworm, delve into the broader field of livestock-specific biotech.

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. Learn more on MRNA stock here.

RSV: The Company reported negligible mRESVIA® sales in the ... Intismeran autogene: Moderna continues to make progress on advancing mRNA-4157 in the clinic. In collaboration with Merck, the Phase 3 ...